Evidence map›Paper›PMID 39904691›Full record

Observational studyThe journal of prevention of Alzheimer's disease2025

Brain health clinics - An evolving clinical pathway?

Anneka F Butters, Jonathan Blackman, Hannah Farouk, Saba Meky, Margaret A Newson, Tomas Lemke, Natalie Rosewell, James A Selwood, Nicholas L Turner, Elizabeth J Coulthard and 1 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The journal of prevention of Alzheimer's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anneka F ButtersSouthmead Hospital, North Bristol NHS Trust, Southmead Road, Westbury-on-Trym, BS10 5NB, UK; ReMemBr Group, University of Bristol Medical School, Level 1, Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK. Electronic address: anneka.butters@bristol.ac.uk.
Jonathan BlackmanSouthmead Hospital, North Bristol NHS Trust, Southmead Road, Westbury-on-Trym, BS10 5NB, UK; ReMemBr Group, University of Bristol Medical School, Level 1, Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK.
Hannah FaroukSouthmead Hospital, North Bristol NHS Trust, Southmead Road, Westbury-on-Trym, BS10 5NB, UK; University of Bath, Claverton Down, Bath, Somerset, BA2 7AY, UK.
Saba MekySouthmead Hospital, North Bristol NHS Trust, Southmead Road, Westbury-on-Trym, BS10 5NB, UK; University of Bath, Claverton Down, Bath, Somerset, BA2 7AY, UK.
Margaret A NewsonSouthmead Hospital, North Bristol NHS Trust, Southmead Road, Westbury-on-Trym, BS10 5NB, UK; ReMemBr Group, University of Bristol Medical School, Level 1, Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK.
Tomas LemkeSouthmead Hospital, North Bristol NHS Trust, Southmead Road, Westbury-on-Trym, BS10 5NB, UK; ReMemBr Group, University of Bristol Medical School, Level 1, Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK; University of Bath, Claverton Down, Bath, Somerset, BA2 7AY, UK.
Natalie RosewellSouthmead Hospital, North Bristol NHS Trust, Southmead Road, Westbury-on-Trym, BS10 5NB, UK.
James A SelwoodSouthmead Hospital, North Bristol NHS Trust, Southmead Road, Westbury-on-Trym, BS10 5NB, UK; ReMemBr Group, University of Bristol Medical School, Level 1, Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK.
Nicholas L TurnerSouthmead Hospital, North Bristol NHS Trust, Southmead Road, Westbury-on-Trym, BS10 5NB, UK; ReMemBr Group, University of Bristol Medical School, Level 1, Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK.
Elizabeth J CoulthardSouthmead Hospital, North Bristol NHS Trust, Southmead Road, Westbury-on-Trym, BS10 5NB, UK; ReMemBr Group, University of Bristol Medical School, Level 1, Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK.
Hilary A ArcherSouthmead Hospital, North Bristol NHS Trust, Southmead Road, Westbury-on-Trym, BS10 5NB, UK; ReMemBr Group, University of Bristol Medical School, Level 1, Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK. Electronic address: hilary.archer@nbt.nhs.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDementia clinics traditionally focus on diagnosis and post-diagnostic care. Awareness is increasing that attention to risk factors and their prevention also forms a key part of dementia management.

objectivesTo describe our Bristol Brain Health clinic including 1) Clinical pathway 2) Patient population 3) Patient experience 4) Evaluation in line with published gold standards. DESIGN/

settingObservational, (longitudinal/retrospective) clinical cohort study of patients attending the North Bristol NHS Trust's Brain Health Service.

participantsOne-hundred and ten patients with mild cognitive disorders attending clinic between 2017- 2023. MEASUREMENTS: We collected data from medical records including clinical assessments, cerebrospinal fluid (CSF) for biomarkers of Alzheimer's Disease (AD), and a lifestyle questionnaire. Descriptive statistics were performed and a clinic evaluation was carried out using recommendations from The European Task Force for Brain Health Services.

resultsAverage age was 63.9 years (SD: 11.2). 74 patients were male (62.8 %). The mean baseline Montreal Cognitive Assessment (MoCA) score was 24.4 (SD: 3.6). 73 patients (66.4 %) received a preventative lifestyle intervention with a review of risk and protective factors for dementia, and development of a bespoke risk reduction plan. Commonly identified risk factors; low mood; n = 61 (55.5 %), hypertension; n = 54 (49.1 %), high cholesterol; n = 42 (47.3 %), and hearing loss; n = 44 (40 %). CSF testing for AD was carried out in 38 individuals and was positive in 17 cases. At last review, one fifth of patients had progressed to dementia. Most common diagnoses; AD; n = 22 (20 %), Functional Cognitive Disorder; n = 16 (14.6 %), Vascular; n = 8 (7.3 %). Patient feedback was good, with all responders recommending the clinic and more than three-quarters of patients being 'extremely likely" to. Clinic evaluation highlighted 'Risk Assessment' and 'Personalised Intervention' as brain health pillar strengths. 'Cognitive Enhancement' was an area for further development.

conclusionsOur patients had access to a range of cutting-edge, diagnostic assessments, in addition to a preventative lifestyle intervention. Our population had a high rate of dementia risk factors and a heterogeneous range of diagnoses. CSF biomarker testing was helpful for differentiating between those with early AD, and others with a multi-factorial presentation. The attendance rates for our preventative intervention suggests patients are receptive to taking a proactive approach to managing risk. This population merits further investigation and continued targeting with preventative measures.

Indexed as

Alzheimer DiseaseCognitive DysfunctionCritical PathwaysAgedBiomarkersFemaleHumansLongitudinal StudiesMaleMiddle AgedRetrospective StudiesRisk FactorsBiomarkersAlzheimer's diseaseBrain HealthCSF biomarkersDementia riskPreventative lifestyle intervention

Identifiers

PMID39904691
PMCPMC11861520

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.